Back to Journals » Stem Cells and Cloning: Advances and Applications » Volume 11

Stem cells for luminal, fistulizing, and perianal inflammatory bowel disease: a comprehensive updated review of the literature

Authors Turse EP, Dailey FE, Naseer M, Partyka EK, Bragg JD, Tahan V

Received 26 June 2018

Accepted for publication 28 September 2018

Published 27 November 2018 Volume 2018:11 Pages 95—113

DOI https://doi.org/10.2147/SCCAA.S135414

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 3

Editor who approved publication: Dr Bernard Binetruy


Erica P Turse, Francis E Dailey, Maliha Naseer, Edward K Partyka, Jack D Bragg, Veysel Tahan

Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Missouri Health Center, Columbia, MO 65212, USA

Abstract: Much research has been performed over the last decade on stem cell therapy as treatment for patients with inflammatory bowel disease. Hematopoietic and mesenchymal stem cells, both allogeneic (from someone else) and autologous (from own patient), have been studied with safe and efficacious results in the majority of patients treated for luminal, perianal, and/or fistulizing disease. Here in this review, we highlight all human trials that have been conducted utilizing stem cell therapy treatment in patients with inflammatory bowel disease.

Keywords: inflammatory bowel disease, Crohn’s disease, ulcerative colitis, mesenchymal, hematopoietic, autologous, allogeneic, therapy, treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]